Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Cancer neoantigens, derived from genetic alterations, are novel proteins recognized by the immune system.
• Neoantigens are crucial targets for cancer immunotherapy, with vaccines aiming to stimulate anti-tumor immunity.
• Advances in sequencing and prediction algorithms enhance neoantigen identification and prioritization.

Purpose of the Study:

• To review and evaluate various cancer neoantigen vaccine platforms.
• To compare the mechanisms of action, advantages, and disadvantages of different vaccine types.
• To summarize early clinical trial findings and discuss future directions in neoantigen vaccine development.

Main Methods:

• Systematic review of literature from PubMed and ClinicalTrials (updated October 2020).
• Evaluation of synthetic long peptide (SLP), RNA, dendritic cell (DC), and DNA vaccine platforms.
• Analysis of mechanisms, clinical experiences, and challenges associated with each platform.

Main Results:

• Several neoantigen vaccine platforms (SLP, RNA, DC, DNA) are under investigation in early clinical trials.
• Initial clinical data suggest promising potential for neoantigen vaccines in cancer immunotherapy.
• The review details the comparative aspects of each vaccine platform's efficacy and safety profile.

Conclusions:

• Neoantigen vaccines hold significant promise for cancer immunotherapy.
• Key challenges include refining neoantigen identification and overcoming the immunosuppressive tumor microenvironment.
• Further research and clinical development are necessary to fully realize the potential of neoantigen vaccines.